GI Innovation (XKRX:358570) Debt-to-Equity : 0.06 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is GI Innovation Debt-to-Equity?

GI Innovation's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩822 Mil. GI Innovation's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩2,812 Mil. GI Innovation's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩58,106 Mil. GI Innovation's debt to equity for the quarter that ended in Mar. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for GI Innovation's Debt-to-Equity or its related term are showing as below:

XKRX:358570' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02 Med: 0.04 Max: 0.06
Current: 0.06

During the past 5 years, the highest Debt-to-Equity Ratio of GI Innovation was 0.06. The lowest was -0.02. And the median was 0.04.

XKRX:358570's Debt-to-Equity is ranked better than
69.65% of 1061 companies
in the Biotechnology industry
Industry Median: 0.14 vs XKRX:358570: 0.06

GI Innovation Debt-to-Equity Historical Data

The historical data trend for GI Innovation's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GI Innovation Debt-to-Equity Chart

GI Innovation Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

-0.06

-0.04

-0.02

0.03

0.05

GI Innovation Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												0.04	0.04	0.05	0.05	0.06

Competitive Comparison of GI Innovation's Debt-to-Equity

For the Biotechnology subindustry, GI Innovation's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GI Innovation's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GI Innovation's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where GI Innovation's Debt-to-Equity falls into.

GI Innovation Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

GI Innovation's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(801.76	+	3471.495)	/	95646.21
	=	0.04

GI Innovation's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(822.432	+	2811.723)	/	58106.203
	=	0.06

GI Innovation (XKRX:358570) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

GI Innovation Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of GI Innovation's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

GI Innovation (XKRX:358570) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GI Innovation Inc (XKRX:358570) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Songpa-daero 167, Room 1116 of A-dong, Songpa-gu, Seoul, KOR, 05855

Website

https://www.gi-innovation.com

GI Innovation Inc is a bio-venture company that researches and develops innovative protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and developing a fusion protein using the GI-SMART platform.

GI Innovation (XKRX:358570) Headlines

No Headlines